verified SJR 1,236 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom

workspace_premium Q1 — Medicine (miscellaneous) lock Subscription

Advances in Therapy

Advances in Therapy is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology (medical) with an H index of 89. It has a price of 3190 €. It has an SJR impact factor of 1,236 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,236.

Advances in Therapy focuses its scope in these topics and keywords: treatment, patients, management, study, editor, clinical, current, efficacy, letter, lumbar, ...

ISSN: 0741-238X

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,236 Q1

H-index 89

Acceptance rate pie_chart

28% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,236

H-index

Docs (year)

303

Docs 3y

1086

Total refs

11688

Cites 3y

4215

Citable 3y

1018

Cites/Doc 2y

3.85

Ref/Doc

38.57

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing

Use of Inhaled Tobramycin in Cystic Fibrosis

Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review

Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search

Cost-Utility of First-Line Actinic Keratosis Treatments in Finland

Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA

Control of allograft rejection in mice by applying a novel neuropeptide, cortistatin

Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials

Clinical Usefulness of Diquafosol for Real-World Dry Eye Patients: A Prospective, Open-Label, Non-Interventional, Observational Study

Clinical experience with an integrated continuous glucose sensor/insulin pump platform: A feasibility study

Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study

SHOW MORE ARTICLES

Breaking Barriers to Effective Type 2 Diabetes Management: Findings from the use of the OPTIMA¬© Questionnaire in Clinical Practice

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components

Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa

Advances in Clinical Cardiology

Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens

A phase 3, randomized, placebo-controlled trial of DepoFoam¬Æ bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes

A Critical Overview of the Biological Effects of Mitomycin C Application on the Cornea Following Refractive Surgery

FAQs

Advances in Therapy has an SJR of 1,236 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Advances in Therapy is 28%.

Advances in Therapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Advances in Therapy?

What is the APC / publication cost?

What is the acceptance rate?